>
-- D -- H -- M
Since Launch
MEET MONOGRAM

The future of orthopedic medicine is personal.

Each year over 1 million knee replacements are performed, contributing to a growing $19.6 Billion market. Invest in Monogram’s mission to transform orthopedic medicine.

Company Highlights

Generating Revenue

Implant sales in 2021 with 2 active distributors

World Class

World-class team

Cadaver Lab

350 sq. ft. cadaver lab complete

8 Patents

8 Patent Applications Filed

$16.7M

Have already raised $16.7M

As Seen In

"Given the sheer number of knee and hip replacement procedures every year, the fact that joint reconstruction technology has remained unchanged for over 50 years is perplexing."

"Monogram has a first-to-market advantage in a sector that's about to get even more competitive."

"Monogram Orthopedics is ushering in personalized orthopedic care by combining proprietary 3D printing technology with next-generation navigated surgical robotics".

"Monogram is developing a better way by commercializing highly personalized joint implants unique to every patient and a first-of-its-kind active robotics system that performs precise bone cuts."

"Monogram has conducted studies with UCLA and demonstrated Monogram process was about seven times more stable than current hip replacement techniques."

Disrupting the Joint Replacement Market

$19.6B

Joint Replacement Market

3.5M

Annual Total Knee Replacement procedures by the year 2030

Over 1M

Knee replacements in US annually

Less than 65 yrs fastest growing demographic

Patients less than 65 years of age represent the fastest-growing population of TKR recipients, expected to account for more than 50% of knee replacement procedures by the year 2030

82% combined share

Four companies currently dominate the multi-billion dollar joint reconstruction market with an 82% combined share in knees

Stryker (Mako) is the only navigated robot arm on the market with a cutting end-effector. Monogram believes we will be the first active navigated arm on the market.

By 2027, approximately 50% of all knee procedures will be robotic, up from 11% in 2019

Significant Increases

in robotic adoption are expected over the next 5-10 years.
At least 50% of procedures will be robotic by 2027
Estimates for procedure volumes vary but TKA projections are generally between 935,000 and 1,260 and 1,260,000 by 2030

50% of early revision total knee arthroplasties related to instability, malalignment or malposition, and failure of fixation.

Knees

Rate of re-admission:

7%-8%.

Approximately 50%-75% are surgical.

36%

Survey: 36% of TKA patients would not have undergone the surgery knowing what it did for them (10 years later).

1 in 5

1 in 5 patients are not satisfied with the results of their total knee replacement.

Potentially Preventable Reasons for revision Procedure
Mechanical Loosening
19%
Other Mechanical Problems
10%
Dislocation/instability
7%
Other mechanical complications
5%
Keep on Moving.

Implants made personally for you. Don’t let knee pain get inyour way of enjoying life to the fullest.

Invest Now
Navigated Robot System
2. Cutting System
3. Implants
4. Navigation Consumables
5. Cutting Tools
6. Software
Navigated Robot System
2. Cutting System
3. Implants
4. Navigation Consumables
5. Cutting Tools
6. Software

The Business Model

We believe that precision implants with precision insertion are the future of orthopaedics. Monograms principal competitive advantage will be our ability to produce customized, robotically inserted orthopaedic implants rapidly and at scale. The product solution architecture we are developing enables rapid fabrication and mass personalization of robotically inserted, patient specific orthopaedic implants.

Invest Now

Building Critical Infrastructure to Scale Growth

Executed Agreements with 2 Distributors with the Expectation to Sign Additional Distributors in Key Markets

We have licensed, FDA-approved, clinically well-established implant components that will be integrated into our proprietary Monogram knee system. Monogram is leveraging the testing and proven performance of these components (articulation, locking mechanisms, inserts) to focus on our novel tibial component and robotics.

Implants designed for uncemented stability.

Monogram implants rely on natural biologic fixation and are smaller, bone conserving, and more stable.

Implant

Monogram Results

Monogram Results: Using Technology to Change the Industry That Has Been Used for the Last 50 Years

Patient-optimized bone sparing press-fit implants

The leading generic equivalent had up to 270% more micromotion than Monogram

The cementless total knee market is expected to grow by $1.2BN from 2020 to 2024 (22% CAGR)

The cementless total knee market is expected to grow by $1.2BN from 2020 to 2024 (22% CAGR)

Approximately 95% of hip implants are press-fit
Will uncemented knee adoption follow the hip trend?
In a period of 10 years, the use of cement decreased from 54% to 4% in 2019. Similarly, we anticipate there could be a significant decrease in the use of cement in knee replacements over the next decade or so.
Invest Now
Tibia

Robotic Surgical Assistants

Monogram’s navigated surgical robot features several enhancements that will improve surgical experiences including:

Closed Loop Tracking

For safety Monogram has implemented a "closed-loop" system. The real-time position of the cutting system is tracked at all times.

Increased Range of Motion

Seven degrees-of-freedom (used to measure range of motion) with control algorithms that leverage the kinematic redundancy to avoid interoperative boundaries and optimize execution.

Active Navigated Milling

High-efficiency rotary cutting system to gently excavate the negative space for the patient-optimized implant.

Developmental Milestones

Monogram is building the future of orthopedics one step at a time

Oct 12, 2017

First patentapplication published

Oct 12, 2017

First patentapplication published

WATCH VIDEO

Oct 12, 2017

First patentapplication published

Oct 12, 2017

First patentapplication published

Oct 12, 2017

First patentapplication published

Oct 12, 2017

First patentapplication published

Oct 12, 2017

First patentapplication published

Oct 12, 2017

First patentapplication published

The Technology Platform

Monogram Orthopaedics is developing a product solution architecture to enable mass personalization of orthopedic implants by linking 3D printing and robotics via automated digital image analysis algorithms.

The Robotics

Monogram’s navigated robot features several enhancements that will improve user experience compared to robots currently in use. Specifically, the Monogram robot will feature tracking cameras mounted directly on the robot to mitigate line-of-sight issues. The robot will feature seven degrees-of-freedom (used to measure range of motion) with control algorithms that leverage kinematic redundancy to avoid inoperative boundaries and optimize surgical execution. The robot will also utilize complex tracking capabilities for soft-tissue avoidance.

Our Implants

Monogram implants are designed such that cortical contact and stability are maximized while remaining insertable and designed to reconstruct the native patient anatomy as closely as possible. Monogram will commercialize the first patient specific hip and knee to address the primary clinical shortcomings of their generic counterparts.

The Technology Platform

Monogram Orthopaedics is developing a product solution architecture to enable mass personalization of orthopedic implants by linking 3D printing and robotics via automated digital image analysis algorithms.

The Robotics

Monogram’s navigated robot features several enhancements that will improve user experience compared to robots currently in use. Specifically, the Monogram robot will feature tracking cameras mounted directly on the robot to mitigate line-of-sight issues. The robot will feature seven degrees-of-freedom (used to measure range of motion) with control algorithms that leverage kinematic redundancy to avoid inoperative boundaries and optimize surgical execution. The robot will also utilize complex tracking capabilities for soft-tissue avoidance.

Our Implants

Monogram implants are designed such that cortical contact and stability are maximized while remaining insertable and designed to reconstruct the native patient anatomy as closely as possible. Monogram will commercialize the first patient specific hip and knee to address the primary clinical shortcomings of their generic counterparts.

Meet the Team

See Our Team

Douglas Unis, Md

Founder & Chief Medical Officer

Dr. Unis is a board-certified attending orthopedic surgeon for the Mount Sinai Health System and Chief of Quality Improvement for Mount Sinai West.

Benjamin Sexson - CEO

CFA, Chief Executive Officer

Prior to joining Monogram, Mr. Sexson served as the Director of R&D and Business Development at Pro-dex (ticker: PDEX). Mr. Sexson graduated with honors from Caltech in Mechanical Engineering and is a CFA Charterholder.

Paul Riss

CPA, MBA, INTERIM CFO

Experienced executive with a demonstrated history of completing SEC filings, focusing on the Securities Exchange Act of 1934 and Section 4(a)(6) of the Securities Act of 1933.  Currently serves as a Director for NetCapital and was a CPA with Ernst & Young.

Kamran Shamaei, P.hD.

VP of Engineering

Kamran Shamaei received a Ph.D. from Yale University and MSc from ETH Zurich and did his postdoctoral research at Stanford University, focusing on Medical Robotics. He has extensive experience developing FDA cleared surgical robots - Dr. Shamaei has worked on robots in early-stage development and actively in use. Before joining Monogram, Dr. Shamaei supported the development of Monarch robots at Auris Health Inc. Before joining Auris, Dr. Shamaei worked with Think Surgical Inc. on the TSolution One Robot, one of the earliest FDA-approved active milling orthopedic robots. Dr. Shamaei was also a Principal Engineer at Motional, leading the planning team in Pittsburgh. He also served as the CTO and co-founder of a stealth startup developing surgical platforms and served as the Director of Platform at Carbon Robotics.

Christopher Scifert, P.hD.

Director of Product Development Implants and Instruments

Chris was the Director of Engineering for Orchid Design, a division of Orchid Orthopedic Solutions, a market-leading outsourced medical services. Chris has held various engineering management roles at Medtronic and Smith & Nephew and obtained a Ph.D. in Biomedical Engineering from the University of Iowa.

Richard Jackson

Director of Software

Before joining Monogram, Richard was a Software and Systems Engineering Manager at Biolase Inc., based in Irvine, CA.  Richard has over 20 years of software engineering experience, including experience in regulated industries, and has held various management roles.

Mark Cole

Director of Quality and Regulatory Assurance

Before joining Monogram, Mark was the Director, Quality and Product Development at Vigilant Biosciences Inc. Mark has over 20 years of experience, including experience in various Quality and Regulatory management roles.

Sophia Sangiorgio, PhD

Director, Orthopaedic Institute for Children

Laura Gilmour

Global Medical B. Development Manager at EOS NA

Matt DiCicco, M.S.

Robotics, MIT

Dr. Roshan Shah

Director of Complex Adult Hip and Knee Reconstruction at Columbia University

Robert Jamieson

Board Certified Orthopaedic Surgeon at The Orthopedic Specialty Center of Northern California

Dr. Matthew E. Heinrich

Total Joint Replacement Specialist at Orthopaedic Specialists of Austin

Darwin Chen

Associate Professor of Orthopaedics at Icahn School of Medicine at Mt Sinai

Dr. Gregory Catlett

Total Joint Replacement Specialist at Orthopaedic Specialists of Austin

Business Updates

Monogram Starts Generating Revenue with First TKA Procedure
about 2 months ago

Monogram is pleased to announce that on Monday, March 22nd, 2021, we completed our first Total Knee Arthroplasty ("TKA") procedure as a company and will now be generating revenue. Facilitating the requirements needed to perform our first case is a significant accomplishment for Monogram and the culmination of a tremendous team effort.  

Monogram is now:

  • HIPAA compliant
  • has implemented an ERP system with lot tracing
  • has secured implant component supply
  • has established distribution relationships
  • has implemented several critical insurance policies
  • has run its first cadaver lab in its Austin facility

"Our philosophy has always been to build an operating business as quickly as possible, which means much more than having competitive products," said CEO Ben Sexson. "The basic infrastructure and systems required to support and scale growth in our highly regulated market are demanding and cannot be overlooked. Pulling all the pieces together to facilitate sales in such a highly regulated market is a major first step towards our goal of building a real orthopedic company.  We believe the first dollars of revenue are always the hardest."

Monogram has not provided sales guidance but would like the investors to calibrate expectations appropriately. "Aggressively driving sales requires a significant working capital investment, and the most compelling components of our product pipeline remain in development and our focus," said CEO Ben Sexson. "We want to build a company that can scale at the appropriate time. The goal right now is forward-thinking, and we are focused on the long-term.  In the long-term, innovative products that improve patient lives are what matter to us most."


Monogram expects to continue generating revenues and remains optimistic about its ongoing growth prospects.


Monogram Executes Strategic License of Unicondylar Knee Replacement Implant
3 months ago

Monogram is pleased to announce it has successfully executed a license agreement for an FDA-approved Unicondylar Knee Arthroplasty ("UKA") implant design from an established orthopedic manufacturer. Monogram intends to prioritize the launch of total knee and partial knee robotic applications.    

"The orthopedic market today is too siloed. Knee teams optimize knee products. Hip teams optimize hip products. Spine products are a completely different focus altogether. After the fact, large organizations try to force-fit platform technologies into these siloes," said CEO Ben Sexson. "Elon Musk explains this organization problem perfectly here. Monogram is building an orthopedic platform technology. We believe an orthopedic robot capable of addressing multiple clinical applications with a single-arm simplifies the capital equipment sales process with hospitals and will be massively differentiated. Integrating partial knees and other products into our robotic platform is critical for this."

Monogram's strategy is to develop a single, highly robust robotic platform technology that can address clinical opportunities across significant orthopedic applications, for example, knees (both total and partial), hips, shoulders, ankles, and spine. Monogram expects to begin developing its partial knee application when it enters V&V testing on its total knee application.

"If you look at Mako and their success, they started with partial knees, and after Stryker acquired them, they launched the total knee application in 2015," said Chief Medical Officer Dr. Doug Unis. "To compete with Mako, at a minimum, we will need robotic prep for both a total knee and a partial knee. Longer-term, we plan on addressing hips and other markets."

Monogram to Present at OTC Markets Regulation A+ Investor Conference - Register now!
4 months ago

Monogram will be speaking Thursday, February 11, 2021, @ 11:30 AM ET at the OTC Markets Regulation A+ Investor Conference.  The presentation is 30 minutes and will include a management Q&A.

Here is the registration link here

Monogram Executes First Hospital Contract: Expect Revenues as early as First Quarter 2021
4 months ago

Monogram is pleased to announce that it has executed a Product Purchase Agreement with its first significant hospital institution.  The company expects it could begin placing implants in patients and generating revenue as early as the first quarter of 2021 (although cautions that Covid-19 and unforeseen market factors could impact timing).    

"Being accepted by the value analysis committee of a major hospital institution is a significant milestone for our company," said CEO Ben Sexson.  "We expect to begin generating revenues very soon.  We continue to execute on our strategic initiatives, and we are extremely pleased with the progress of our product pipeline and our pace of growth.  Our goal is to become a competitor in the ortho space as quickly as possible."


Monogram management looks forward to sharing our continued progress and is thankful for our shareholders without whom this progress would not have been possible.

Live Robotics Investor Webinar with Q&A

Join Matt Taylor, CFA Managing Director at UBS and Monogram's CEO Ben Sexson, and CMO Doug Unis in a live discussion of all things ortho, no holds barred! The orthopedic market is rapidly evolving with numerous forces at play. Join us for an unscripted discussion about what could be next for this fascinating market!

About Matt Taylor, CFA:

Matt Taylor is a Managing Director and leads coverage of US Medical Supplies and Devices equity research at UBS. Matt has received recognition for his work as a MedTech analyst, achieving a top-5 position and 'runner-up' ranking in the 2019 Institutional Investor poll and he was named an 'up-and-comer' in the 2011-13 surveys. Prior to joining UBS, Matt was the senior analyst covering Medical Supplies and Devices at Barclays, joining the organization as a senior associate in 2009. Matt also worked at an associate analyst in MedTech at BMO Capital Markets from 2007-2009 and began his career in finance working in a business risk role at Morgan Stanley. Matt was trained as a biomedical engineer and holds a BS in Biomedical Engineering from Boston University, an MBA from Fordham University, participating in the Beijing MBA program, and is a CFA Charterholder.
Thursday, SEPTEMBER 30, 10:00 AM EST
RESERVE YOUR SEAT